Important Notice Regarding Alleged Barostim Kickback and False Claims Misrepresentations. Shareholders allege that CVRx's heart failure revenue growth rested in part on unlawful sales practices tied to government health programs.
NEW YORK, Nov. 19, 2026 /PRNewswire/ -- SueWallSt notifies investors in CVRx, Inc. (Nasdaq: CVRX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between July 25, 2023 and August 6, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
CVRx cited a $2.2 billion U.S. annual market opportunity for Barostim. The lawsuit contends that some of the growth behind that figure came from kickbacks and false claims, in what it describes as a medical device securities fraud. CVRx shares lost 60%, or $3.55 per share, after the Company's August 6, 2026 disclosures, which included a U.S. Department of Justice civil investigative demand under the False Claims Act. Applications to serve as lead plaintiff must be filed by January 8, 2027.
The Alleged Kickback and False Claims Sales Methodology
The complaint alleges that CVRx and/or its employees used three practices to drive sales growth. They allegedly marketed Barostim improperly, offered or paid kickbacks to healthcare providers, and gave false information to government health insurance programs. Barostim is the only device CVRx sells, so the alleged conduct reached the Company's entire revenue base.
Key Medical Device Securities Fraud Allegations for Shareholders
- Improper marketing and kickbacks: Barostim sales growth was allegedly induced through improper marketing and payments to healthcare providers, in alleged violation of the Anti-Kickback Statute.
- False information to government payors: CVRx allegedly provided false information to government health insurance programs, which is conduct the False Claims Act prohibits.
- Revenue quality: Reported revenue was allegedly, in part, the product of unlawful conduct and therefore unsustainable.
- Undisclosed liability risk: The alleged practices increased the Company's risk of criminal and civil liability.
- Compliance and controls claims: Statements on False Claims Act and Anti-Kickback Statute compliance, on reimbursement strategy, and on internal controls are alleged to have been materially false and misleading.
The Medicare Reimbursement Factor
Government reimbursement sits at the center of the Barostim business. Nearly two-thirds of the device's target patients are over age 65. Starting January 1, 2024, Medicare's New Technology APC 1580 assignment for Barostim carried an average payment of $45,000.
According to the lawsuit, this reliance on federal programs is why the alleged conduct matters to shareholders. False Claims Act penalties can reach up to three times the government's damages, and a violation may provide a basis for exclusion from federally funded healthcare programs.
"This case presents important questions about compliance disclosure obligations in the medical device sector, particularly for a company that relies on a single implantable product reimbursed largely through Medicare. The complaint alleges that investors evaluating CVRx's reported growth were not told it depended in part on sales practices now under federal False Claims Act scrutiny." -- Joseph E. Levi, Esq.
Submit your information here or call (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the CVRX Lawsuit
Q: Who is eligible to join the CVRX investor lawsuit? A: Investors who purchased CVRX stock or securities between July 25, 2023 and August 6, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did CVRX stock drop? A: Shares fell approximately 60%, a decline of $3.55 per share, after the Company disclosed a U.S. Department of Justice civil investigative demand under the False Claims Act and lowered its guidance. Investors who purchased shares during the Class Period at allegedly artificially inflated prices and suffered losses may be eligible to seek compensation.
Q: What specific misstatements does the CVRX lawsuit allege? A: The complaint alleges that CVRx, Inc. made materially false or misleading statements during the Class Period about the drivers of its reported Barostim revenue growth, its compliance with the False Claims Act and Anti-Kickback Statute, and the effectiveness of its internal controls. When the Department of Justice civil investigative demand was disclosed on August 6, 2026, the stock price declined sharply.
Q: What do CVRX investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.
Q: What happens after I provide my information? A: Your trading history will be reviewed at no cost for an initial assessment of your potential eligibility.
Q: What if I already sold my CVRX shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, these cases are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE SueWallSt.com

Share this article